Next-Generation Bispecific Nanobody Targeting CD4 and FCGR3A for Innovative HIV Infection Therapy

VHH-P741 is a humanized bispecific nanobody currently in the Biological Testing stage, designed for the potential treatment of HIV infection. This novel therapeutic candidate targets two critical proteins: CD4 molecule (CD4) and Fc gamma receptor IIIa (FCGR3A). By engaging both CD4 and FCGR3A, VHH-P741 is positioned to leverage key immune mechanisms involved in HIV pathogenesis and clearance. This approach represents a promising strategy to address the unmet needs in HIV infection, aiming for enhanced efficacy and improved immune activation.

Licensing Opportunity

VHH-P741 is now available for out-licensing or partnership opportunities. We invite collaboration with industry partners interested in advancing cutting-edge bispecific nanobody therapies for HIV infection.

Development Phase

Modality

VHH-P741 utilizes a bispecific format composed of two single-domain camelid-derived antibodies against CD16A, fused to a single domain recognizing CD4-bound HIV-1 envelope glycoprotein via a flexible (G4S)3 linker, and is expressed in an E. coli system. The nanobody structure, characterized by its small molecular size and single-domain architecture, offers significant advantages such as superior tissue penetration and robust stability. These properties are particularly beneficial for targeting immune cell interactions within the complex microenvironment of HIV infection, supporting innovative mechanisms of viral suppression and cellular immune engagement.

Target

CD4 and FCGR3A are central targets in HIV infection immunotherapy. CD4 is a surface protein found predominantly on T-helper lymphocytes, playing a pivotal role in immune signaling and acting as a primary receptor for HIV entry. FCGR3A is mainly expressed on natural killer (NK) cells and certain macrophages, mediating antibody-dependent cellular cytotoxicity (ADCC). Strategic targeting of CD4 disrupts HIV's ability to infect new cells, while engaging FCGR3A enhances NK cell-mediated clearance of infected cells. By focusing on both CD4 and FCGR3A, VHH-P741 offers dual intervention—blocking viral entry and potentiating immune effector functions—an approach with significant strategic and therapeutic appeal for advancing HIV infection management.

Mechanism of Action

VHH-P741 exerts its activity through simultaneous engagement of CD4 on target cells and FCGR3A on effector cells. This dual targeting directs NK cells to HIV-infected CD4-positive cells by bridging FCGR3A and CD4, resulting in selective activation of antibody-dependent cellular cytotoxicity (ADCC) against the infected population. The bispecific nanobody format facilitates efficient synapse formation between NK and target cells, promoting immune clearance. Leveraging a nanobody platform, VHH-P741 can be further adapted for advanced therapeutic modalities, such as antibody-drug conjugates or additional bispecific constructs, broadening the landscape of HIV immunotherapy.

Hiv Infection

HIV infection remains a major global health burden, with millions living with the virus and thousands of new cases reported annually. Standard treatments comprise antiretroviral therapy, which effectively suppresses viral replication but requires lifelong adherence and cannot eradicate latent reservoirs. These limitations highlight persistent challenges in treatment resistance, toxicity, long-term management, and the absence of a definitive cure. Consequently, novel therapeutic strategies are in high demand. VHH-P741's mechanism—combining selective targeting of infected CD4-positive cells and harnessing the cytolytic potential of FCGR3A-positive cells—addresses critical gaps in current therapy by activating immune-mediated clearance pathways and potentially reducing the burden of persistent infection. Its unique bispecific nanobody format offers new possibilities for functional HIV cure strategies and next-generation immunotherapies.